Ones To Watch News
Refine Search
Biotechnology
Allergy Therapeutics today said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary goal, with the news sending the UK biotech’s shares up 20.8% to 1.80 pence. 14 November 2023
Pharmaceutical
Boston, USA-based PureTech Health saw its London-listed share edge up 1.6% to 176.00 pence, after it announced top-line results from its Phase IIa, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone) in anxiety. 14 November 2023
Biotechnology
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
Biotechnology
Legend Biotech Corporation has entered into an exclusive, global license agreement with Swiss pharma giant Novartis. 13 November 2023
Biotechnology
Dutch biotech company VectorY Therapeutics today announced the close of a 129 million-euro ($138 million) Series A financing. 13 November 2023
Biotechnology
US neuroscience-focused biopharma Neurocrine Biosciences today announced that it has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of Ingrezza (valbenazine) prior to the expiration of applicable Neurocrine patents. 13 November 2023
Pharmaceutical
UK-based Kelso Pharma today revealed it has taken its first step in its European expansion strategy by agreeing to acquire Italy’s Velit Biopharma which, like Kelso is a specialty pharma company. 13 November 2023
Pharmaceutical
US clinical-stage liver disease specialist Madrigal Pharmaceuticals’ shares gained 1.8% to $138.84 on Friday, as it announced new data from the Phase III MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom. 13 November 2023
Biotechnology
Cambridge, UK-based drug discovery and development company Mission Therapeutics today announced the publication of a peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD)’ in the journal Nature Communications. 13 November 2023
Pharmaceutical
Poolbeg Pharma has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. 10 November 2023
Biotechnology
UK-based Barinthus Biotherapeutics today presented data from two hepatitis B virus (HBV) clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2023. 10 November 2023
Biotechnology
UK oncology-focussed biotech ValiRx edged up 2.5% to 12.30 pence this morning, after it announced it has entered into an agreement with StingRay Bio to investigate a lead series of drug candidates for use in oncology. 10 November 2023
Biotechnology
A Phase II failure for Californian cell therapy company Atara Biotherapeutics has prompted a share sell-off, with the company’s stock falling 80% in value on Thursday. 10 November 2023
Biotechnology
A biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, is to go by a new name. 7 November 2023
Biotechnology
A collaboration between Senti Biosciences and Celest Therapeutics will see the latter gain rights to develop SENTI-301A in China. 7 November 2023
Biotechnology
Having previously had disappointing results from its investigational drug, Kodiak Sciences yesterday announced that its Phase III GLOW superiority study evaluating tarcocimab tedromer 5mg in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint. 7 November 2023
Pharmaceutical
UK-headquartered specialty pharmaceutical company Advanz Pharma today announced it expands its specialty brands portfolio with the signing of the acquisition of global rights of Androcur (cyproterone acetate) from German pharma major Bayer. 7 November 2023
Biotechnology
Acelyrin has appointed Patricia Turney as chief technical operations officer. 6 November 2023
Biotechnology
Kronos Bio is to cut around 19% of its staff as part of a plan to extend its cash runway into 2026. 6 November 2023
Biotechnology
Shares of German biotech BioNTech were up 5.3% at $100.91, despite joining the list of companies with downturned sales and earnings as the COVID-19 pandemic subsides. 6 November 2023
Pharmaceutical
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Biotechnology
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Biotechnology
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Pharmaceutical
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Biotechnology
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
Biotechnology
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Biotechnology
US clinical-stage biotech Spyre Therapeutics says it has appointed of Sheldon Sloan as its chief medical officer (CMO). 3 October 2024
Biotechnology
US biotech Triveni Bio has announced a $115 million Series B to support pipeline expansion. 3 October 2024
Biotechnology
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
Biotechnology
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Pharmaceutical
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Biotechnology
American biotech Shattuck Labs has announced plans to reduce its workforce by approximately 40%, bringing its employee count below 50. 2 October 2024
Pharmaceutical
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Biotechnology
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Pharmaceutical
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Biotechnology
US vaccine company Gritstone bio closed 62% lower after Tuesday’s trading. 2 October 2024
Biotechnology
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze